Jiro Ito1, Kazuma Nagata2, Susumu Sato3, Akira Shiraki4, Naoki Nishimura5, Shinyu Izumi6, Ryo Tachikawa3, Takeshi Morimoto7, Keisuke Tomii1. 1. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. 2. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. Electronic address: kazuma_n1101@yahoo.co.jp. 3. Graduate School of Medicine, Kyoto University, Kyoto, Japan. 4. Ogaki Municipal Hospital, Gifu, Japan. 5. St. Luke's International Hospital, Tokyo, Japan. 6. National Center for Global Health and Medicine, Tokyo, Japan. 7. Clinical Research Center, Kobe City Medical Center General Hospital, Kobe, Japan; Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
Abstract
BACKGROUND: High-flow nasal cannula oxygen therapy (HFNC) is widely used mainly in the acute care setting, but limited data are available on real-world practice in adults. The objective of this study was to describe HFNC practices in Japanese adults. METHODS: A retrospective cross-sectional multicenter survey of adult patients receiving HFNC from January through March 2015 was conducted in 33 participating hospitals in Japan. RESULTS: We obtained information on 321 patients (median age, 76; 218 men, 103 women; median estimated PaO2/FIO2, 178 mm Hg) from 22 hospitals. Do-not-intubate status was determined in 37.4% of patients. Prior to HFNC, 57.9% of patients received conventional oxygen therapy; 25.9%, noninvasive ventilation; and 15.0%, invasive mechanical ventilation. The common indications for HFNC were acute hypoxemic respiratory failure (ARF) (65.4%), postoperative respiratory support (15.9%), and post-extubation respiratory support (11.2%). The underlying etiology of ARF included interstitial lung disease, pneumonia, and cardiogenic pulmonary edema. HFNC was administered mostly in intensive care units or intermittent care units (60.7%) and general wards (36.1%). Median duration of HFNC was 4 days; median total flow rate, 40 L/min; and median FIO2, 50%. HFNC significantly improved PaO2, PaCO2, SpO2 and respiratory rate from baseline. Two-thirds of patients finally survived to be discharged or transferred. CONCLUSIONS: We documented patient demographics, clinical indications, and settings of HFNC use in the real world. We also demonstrated positive effects of HFNC on respiratory parameters. Further studies are urgently needed regarding the efficacy and safety of HFNC in populations outside of previous clinical trials.
BACKGROUND: High-flow nasal cannula oxygen therapy (HFNC) is widely used mainly in the acute care setting, but limited data are available on real-world practice in adults. The objective of this study was to describe HFNC practices in Japanese adults. METHODS: A retrospective cross-sectional multicenter survey of adult patients receiving HFNC from January through March 2015 was conducted in 33 participating hospitals in Japan. RESULTS: We obtained information on 321 patients (median age, 76; 218 men, 103 women; median estimated PaO2/FIO2, 178 mm Hg) from 22 hospitals. Do-not-intubate status was determined in 37.4% of patients. Prior to HFNC, 57.9% of patients received conventional oxygen therapy; 25.9%, noninvasive ventilation; and 15.0%, invasive mechanical ventilation. The common indications for HFNC were acute hypoxemic respiratory failure (ARF) (65.4%), postoperative respiratory support (15.9%), and post-extubation respiratory support (11.2%). The underlying etiology of ARF included interstitial lung disease, pneumonia, and cardiogenic pulmonary edema. HFNC was administered mostly in intensive care units or intermittent care units (60.7%) and general wards (36.1%). Median duration of HFNC was 4 days; median total flow rate, 40 L/min; and median FIO2, 50%. HFNC significantly improved PaO2, PaCO2, SpO2 and respiratory rate from baseline. Two-thirds of patients finally survived to be discharged or transferred. CONCLUSIONS: We documented patient demographics, clinical indications, and settings of HFNC use in the real world. We also demonstrated positive effects of HFNC on respiratory parameters. Further studies are urgently needed regarding the efficacy and safety of HFNC in populations outside of previous clinical trials.
Authors: Michael E Wilson; Aniket Mittal; Bibek Karki; Claudia C Dobler; Abdul Wahab; J Randall Curtis; Patricia J Erwin; Abdul M Majzoub; Victor M Montori; Ognjen Gajic; M Hassan Murad Journal: Intensive Care Med Date: 2019-10-28 Impact factor: 41.787
Authors: Pablo Cruces; Jaime Retamal; Daniel E Hurtado; Benjamín Erranz; Pablo Iturrieta; Carlos González; Franco Díaz Journal: Crit Care Date: 2020-08-10 Impact factor: 9.097
Authors: Bram Rochwerg; Sharon Einav; Dipayan Chaudhuri; Jordi Mancebo; Tommaso Mauri; Yigal Helviz; Ewan C Goligher; Samir Jaber; Jean-Damien Ricard; Nuttapol Rittayamai; Oriol Roca; Massimo Antonelli; Salvatore Maurizio Maggiore; Alexandre Demoule; Carol L Hodgson; Alain Mercat; M Elizabeth Wilcox; David Granton; Dominic Wang; Elie Azoulay; Lamia Ouanes-Besbes; Gilda Cinnella; Michela Rauseo; Carlos Carvalho; Armand Dessap-Mekontso; John Fraser; Jean-Pierre Frat; Charles Gomersall; Giacomo Grasselli; Gonzalo Hernandez; Sameer Jog; Antonio Pesenti; Elisabeth D Riviello; Arthur S Slutsky; Renee D Stapleton; Daniel Talmor; Arnaud W Thille; Laurent Brochard; Karen E A Burns Journal: Intensive Care Med Date: 2020-11-17 Impact factor: 17.440